首页> 外文期刊>Journal of Traditional and Complementary Medicine >A population-based case-control study on the association of Angelica sinensis exposure with risk of breast cancer
【24h】

A population-based case-control study on the association of Angelica sinensis exposure with risk of breast cancer

机译:一种基于人口的案例对照研究 Angelica Sinensis

获取原文
           

摘要

BackgroundDue to a lack of evidence from large-scale epidemiological studies by far on this issue, whether there is a link betweenAngelica sinensisexposure and breast cancer risk remained inconclusive.MethodsWe conducted a population-based case-control study using Taiwan’s National Health Insurance claim data, in which all breast cancer patients newly diagnosed between 2005 and 2008 were employed as the case group (n?=?34,262) and a random sample of non-breast cancer individuals selected from 1-million beneficiaries registered in 2005 was served as the control group. For fair comparability, we employed the time density sampling method to select controls who were matched to case on date of breast cancer diagnosis and age with a case/control ratio of 1/3 (n?=?102,786).ResultsWe found that the use ofAngelica sinensispresents a weakly but significantly protective effect on breast cancer (adjusted odds ratio (aOR) 0.95, 95% confidence interval (CI) 0.93–0.98), with a significant dose-gradient relationship. We also noted a stronger association with breast cancer with initial use ofAngelica sinensisat a longer time before breast cancer diagnosis, and found that the seemingly protective effect ofAngelica sinensiswas more obvious among women who had initial use at 47–55 years (aOR 0.93, 95% CI 0.88–0.98).ConclusionThis population-based case-control study revealed that exposure toAngelica sinensisshowed a weakly but significantly protective effect on breast cancer risk, which could ease people’s concern over the potential carcinogenic effect from exposure toAngelica sinensis.
机译:BackgroundDue在缺乏来自大规模流行病学研究的证据对这个问题,是否存在与久理中的链接,angangelica SinensIseXposure和乳腺癌风险仍然不协调。近奇地区使用台湾全国医疗保险索赔数据进行了一项基于人口的案例控制研究,其中,在2005年至2008年间新诊断的乳腺癌患者被雇用为案例组(N?= 34,262),并作为对照组担任2005年注册的1000万名受益人的非乳腺癌个体随机样品。为了相当可比性,我们采用时间密度采样方法选择与乳腺癌诊断和年龄的案例相匹配的控制,案例/控制比为1/3(n?= 102,786).resultwe发现使用Ofhangelica Sinensispresents对乳腺癌(调节的差距(AOR)0.95,95%置信区间(CI)0.93-0.98)具有显着的保护作用,具有显着的剂量梯度关系。我们还注意到乳腺癌初始使用的乳腺癌较长的时间较长的时间乳腺癌诊断前的时间较长的时间,并发现在47-55岁的女性初始使用的女性中的看似保护作用更明显(AOR 0.93,95% CI 0.88-0.98)。合并基于人群的案例对照研究,显示出暴露的TOANGELICA SINENSISS对乳腺癌风险的弱而显着的保护作用,这可以缓解人们对暴露于anghelica sinensis的潜在致癌作用的关注。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号